Latest News & Features
Americas
The first US court decision applying the Myriad decision has landed, and it makes for interesting reading, as Antoinette Konski reports. 3 December 2013
Europe
Genomic Vision develops genetic screening tests for diagnostics and research. In the aftermath of the Myriad ruling, how can it use IP to develop market share? LSIPR spoke to chief executive Aaron Bensimon to find out. 4 November 2013
Biotechnology
Ethical considerations plus the ambiguity of the Biotech Directive are factors influencing the patentability of totipotent stem cells, says Andrew Sanderson. 4 November 2013
Asia
Many of the world’s biggest selling drugs have lost exclusivity in recent years, presenting huge opportunities for generic drugs companies but, as LSIPR finds out, it doesn’t have to be a dead end for the innovators. 16 October 2013
Americas
New guidelines for the examination of biotechnology inventions in Brazil provide useful support for applicants, as Gabriel Di Blasi and Alexandre Santos explain. 16 October 2013
Biotechnology
When the US Supreme Court decided in favour of Monsanto in its case against a soybean farmer, it clarified the patent status of certain self-replicating technologies. In Europe, the result would probably have been the same, say Steven Zeman and Heike Vogelsang-Wenke. 16 October 2013
Biotechnology
Frances Salisbury and Lindsey Woolley look at the complex business of patenting agricultural products in Europe. 16 October 2013
Americas
In the life sciences sector, defending broad patent claims can be a tricky business, says Gordon Wright. 16 October 2013
Biotechnology
When it comes to plants, European courts have been occupied with various debates over salad. Margreet van Heuvel and Bart Swinkels take a look. 16 October 2013
Asia
LSIPR spoke to Jörg Thomaier, chief IP counsel at Bayer, about the state of protection in emerging jurisdictions and the challenges the global company faces in asserting its IP across the world. 16 October 2013